Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. Its include TTI-622, a SIRPa-IgG4 Fc fusion protein that is designed to enhance macrophage-mediated phagocytosis and anti-tumor activity by blocking the CD47, which is in Phase 1 clinical trials; and TTI-621, a SIRPa-IgG1 Fc fusion protein, which is in Phase 1 clinical trials and generates a signal blocking the CD47 for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was incorporated in 2004 is based in Mississauga, Canada.
IPO Year: n/a
Exchange: NASDAQ
Website: trilliumtherapeutics.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/17/2021 | Buy → Hold | The Benchmark Company | |
| 11/17/2021 | Buy → Hold | Benchmark | |
| 8/24/2021 | $21.00 → $18.50 | Buy → Hold | Craig-Hallum |
| 8/24/2021 | Market Outperform → Market Perform | JMP Securities | |
| 8/23/2021 | $22.00 → $18.50 | Buy → Neutral | HC Wainwright & Co. |
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Trillium Therapeutics Inc. (0001616212) (Issuer)
4 - Trillium Therapeutics Inc. (0001616212) (Issuer)
4 - Trillium Therapeutics Inc. (0001616212) (Issuer)
4 - Trillium Therapeutics Inc. (0001616212) (Issuer)
4 - Trillium Therapeutics Inc. (0001616212) (Issuer)
4 - Trillium Therapeutics Inc. (0001616212) (Issuer)
4 - Trillium Therapeutics Inc. (0001616212) (Issuer)
4 - Trillium Therapeutics Inc. (0001616212) (Issuer)
4 - Trillium Therapeutics Inc. (0001616212) (Issuer)
4 - Trillium Therapeutics Inc. (0001616212) (Issuer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
The Benchmark Company downgraded Trillium Therapeutics from Buy to Hold
Benchmark downgraded Trillium Therapeutics from Buy to Hold
Craig-Hallum downgraded Trillium Therapeutics from Buy to Hold and set a new price target of $18.50 from $21.00 previously
JMP Securities downgraded Trillium Therapeutics from Market Outperform to Market Perform
HC Wainwright & Co. downgraded Trillium Therapeutics from Buy to Neutral and set a new price target of $18.50 from $22.00 previously
Benchmark initiated coverage of Trillium Therapeutics with a rating of Buy and set a new price target of $21.00
The Benchmark Company initiated coverage of Trillium Therapeutics with a rating of Buy and set a new price target of $21.00
15-12B - Trillium Therapeutics Inc. (0001616212) (Filer)
EFFECT - Trillium Therapeutics Inc. (0001616212) (Filer)
EFFECT - Trillium Therapeutics Inc. (0001616212) (Filer)
S-8 POS - Trillium Therapeutics Inc. (0001616212) (Filer)
POSASR - Trillium Therapeutics Inc. (0001616212) (Filer)
S-8 POS - Trillium Therapeutics Inc. (0001616212) (Filer)
POS AM - Trillium Therapeutics Inc. (0001616212) (Filer)
POS AM - Trillium Therapeutics Inc. (0001616212) (Filer)
8-K - Trillium Therapeutics Inc. (0001616212) (Filer)
25-NSE - Trillium Therapeutics Inc. (0001616212) (Subject)
Fastest customizable press release news feed in the world
Mr. Parsons served as the Chief Financial Officer of Trillium Therapeutics, which was recently acquired by Pfizer Inc. SAN DIEGO and CALGARY, AB, June 17, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), today announced the voting results from its Annual General Meeting (AGM) of Shareholders held on Thursday, June 16, 2022. A total of 40.43% of the issued and outstanding common shares of the Corporation were represented either in person or by proxy at the meeting. Additionally, James T. Parsons was elected to the Oncolytics Biotech Board of Directors. Leonard (Leon) Kruimer did not stand for re-election as a director at the AGM. Mr. Parsons commented, "Oncolytics' clini
CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. ("Trillium" or the "Company") (TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, is pleased to announce that it has received a final order from the Supreme Court of British Columbia approving the previously announced plan of arrangement (the "Arrangement") with PF Argentum ULC ("PF Argentum"), a wholly-owned, indirect subsidiary of Pfizer Inc. (NYSE:PFE) ("Pfizer"). Pursuant to the Arrangement, PF Argentum will acquire all of the issued and outstanding shares and warrants of Trillium other than Trillium securities owned by Pfizer and its affiliates
Frazier Healthcare Partners announced today the closing of Frazier Life Sciences Public Fund, L.P., exceeding its target and closing on nearly $830 million in capital commitments in an oversubscribed fundraise. Led by Managing Partner Albert Cha, General Partner and Portfolio Manager Jamie Brush, and Managing Partners Patrick Heron and James Topper, Frazier Life Sciences Public Fund is a long-only fund investing in small- and mid-cap public biotech companies. Frazier Life Sciences Public Fund marks Frazier's first dedicated public life sciences fund, bringing the firm's total committed capital raised since inception to over $7.1 billion. "We are thrilled to announce the launch of our publ
Frazier Healthcare Partners announced today the promotion of four Life Sciences team members: Jamie Brush, M.D., to General Partner and Portfolio Manager, David Topper to Partner, Capital Markets, Liz Park to Principal, Investor Relations, and Joe Cabral to Senior Associate. Dr. Brush joined the Frazier Life Sciences team in 2016 and co-leads Frazier's public equity investment strategy. He is the co-portfolio manager for Frazier Life Sciences Public Fund, an $830 million long-only fund that invests in small- and mid-cap public biotech companies. He led Frazier's public investments in Trillium Therapeutics (NASDAQ:TRIL, pending acquisition by Pfizer))), Translate Bio (NASDAQ:TBIO, acquired
CAMBRIDGE, Mass., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. ("Trillium" or the "Company") (TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that its securityholders approved a statutory arrangement with PF Argentum ULC ("PF Argentum") a wholly-owned, indirect subsidiary of Pfizer Inc. (NYSE:PFE) ("Pfizer") at the special meeting of Trillium securityholders today. Pursuant to the arrangement, PF Argentum will acquire all of the issued and outstanding shares and warrants of Trillium, other than Trillium securities owned by Pfizer and its affiliates. The special resolution approving the arrange
Proposed acquisition strengthens Pfizer's category leadership in Oncology with addition of next-generation, investigational immuno-therapeutics for hematological malignancies Expands innovative pipeline, potentially enhancing growth in 2026-2030 and beyond Pfizer to host analyst and investor call at 10:00 a.m. ET today with Pfizer Oncology executives Pfizer Inc. (NYSE:PFE) and Trillium Therapeutics Inc. (TSX:TRIL) today announced that the companies have entered into a definitive agreement under which Pfizer will acquire Trillium, a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. Under the terms of the agreement, Pfizer will acquire al
CAMBRIDGE, Mass., Aug. 13, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today reported financial and operating results for the three and six months ended June 30, 2021. All financial amounts in this news release are in United States dollars, unless otherwise stated. "The second quarter 2021 was an important period for Trillium, during which time we communicated our go-forward strategy and began executing against it," said Jan Skvarka, Trillium's President and CEO. "We announced seven priority indications and nine patient settings, with six studies expected to initiate i
CAMBRIDGE, Mass., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has dosed the first TP53-mutated acute myeloid leukemia (AML) patient with TTI-622 (SIRPα-IgG4 Fc), an investigational checkpoint inhibitor of the innate immune system, in combination with azacitidine. TTI-622 is a fusion protein that is designed to block the inhibitory activity of CD47, a molecule that is overexpressed by a wide variety of tumors. CD47 binds to SIRPα on macrophages and delivers a "don't eat me" signal that inhibits the ability of macrophages to engulf and
CAMBRIDGE, Mass., July 06, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has dosed the first acute myeloid leukemia (AML) patient with TTI-622 (SIRPα-IgG4 Fc), an investigational checkpoint inhibitor of the innate immune system, in combination with azacitidine and venetoclax. TTI-622 is a fusion protein that is designed to block the inhibitory activity of CD47, a molecule that is overexpressed by a wide variety of tumors. CD47 binds to SIRPα on macrophages and delivers a "don't eat me" signal that inhibits the ability of macrophages to engulf and
CAMBRIDGE, Mass., June 30, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. ("Trillium" or the "Company") (TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the appointment of pharmaceutical industry leader Catherine Mackey, Ph.D., to its Board of Directors, effective immediately. "We are excited to welcome Dr. Mackey to our board of directors," said Paolo Pucci, Lead Director of Trillium. "Her significant executive experience and expertise leading research and development organizations will be invaluable as Trillium advances its two lead product candidates into a Phase 1b/2 program." Dr. Mackey has more t
Live finance-specific insights
Proposed acquisition strengthens Pfizer's category leadership in Oncology with addition of next-generation, investigational immuno-therapeutics for hematological malignancies Expands innovative pipeline, potentially enhancing growth in 2026-2030 and beyond Pfizer to host analyst and investor call at 10:00 a.m. ET today with Pfizer Oncology executives Pfizer Inc. (NYSE:PFE) and Trillium Therapeutics Inc. (TSX:TRIL) today announced that the companies have entered into a definitive agreement under which Pfizer will acquire Trillium, a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. Under the terms of the agreement, Pfizer will acquire al
Live Leadership Updates
Mr. Parsons served as the Chief Financial Officer of Trillium Therapeutics, which was recently acquired by Pfizer Inc. SAN DIEGO and CALGARY, AB, June 17, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), today announced the voting results from its Annual General Meeting (AGM) of Shareholders held on Thursday, June 16, 2022. A total of 40.43% of the issued and outstanding common shares of the Corporation were represented either in person or by proxy at the meeting. Additionally, James T. Parsons was elected to the Oncolytics Biotech Board of Directors. Leonard (Leon) Kruimer did not stand for re-election as a director at the AGM. Mr. Parsons commented, "Oncolytics' clini
CAMBRIDGE, Mass., June 30, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. ("Trillium" or the "Company") (TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the appointment of pharmaceutical industry leader Catherine Mackey, Ph.D., to its Board of Directors, effective immediately. "We are excited to welcome Dr. Mackey to our board of directors," said Paolo Pucci, Lead Director of Trillium. "Her significant executive experience and expertise leading research and development organizations will be invaluable as Trillium advances its two lead product candidates into a Phase 1b/2 program." Dr. Mackey has more t
MENLO PARK, Calif.--(BUSINESS WIRE)--Frazier Healthcare Partners announced the promotion of several members on its Life Sciences team: Aditya Kohli to Venture Partner, Anna Chen to Vice President, and Max Nowicki to Senior Associate. Aditya Kohli, Ph.D., joined the Frazier Life Sciences team in 2016 and focuses on company creation. He co-founded Phathom Pharmaceuticals (NASDAQ: PHAT) and Scout Bio, and helped launch Passage Bio (NASDAQ: PASG). Dr. Kohli serves as the Chief Business Officer of Phathom Pharmaceuticals and as a member of the board of directors for Scout Bio. Anna Chen, Ph.D., joined Frazier in 2018 and focuses on evaluating investment opportunities and creating new
This live feed shows all institutional transactions in real time.
SC 13D/A - Trillium Therapeutics Inc. (0001616212) (Subject)
SC 13G/A - Trillium Therapeutics Inc. (0001616212) (Subject)
SC 13G/A - Trillium Therapeutics Inc. (0001616212) (Subject)
SC 13G - Trillium Therapeutics Inc. (0001616212) (Subject)
SC 13G/A - Trillium Therapeutics Inc. (0001616212) (Subject)
SC 13G/A - Trillium Therapeutics Inc. (0001616212) (Subject)
SC 13G - Trillium Therapeutics Inc. (0001616212) (Subject)